Gypenosides Treatment for Optic Neuritis

Phase 2

Terminated

• Conditions: Optic Neuritis
• Interventions: Drug: Placebo; Drug: Gypenosides

• Registration Number: NCT02976766
• Lead Sponsor: First Affiliated Hospital of Guangxi Medical University

Brief Summary

The purpose of this study is to determine whether gypenosides are neuroprotective in patients with acute optic neuritis.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-11-24
• Study First Submitted QC: 2016-11-25
• Study First Posted: 2016-11-29
• Study Start: 2017-02-04
• Primary Completion: 2020-12-31
• Study Completion: 2020-12-31
• Status Verified: 2021-04
• Last Update Submitted: 2021-04-07
• Last Update Posted: 2021-04-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	-
Gypenosides	Gypenosides	-

Primary Outcome Measures

Name	Time	Method
Mean retinal nerve fibre layer thickness	6 months

Secondary Outcome Measures

Name	Time	Method
Mean visual field defect	6 months
Number of participants with Adverse events	Screening until end of study
Total macular volume	6 months
Best corrected visual acuity	6 months
Latency and amplitude of visual evoked potentials	6 months

Trial Locations

Locations (1)

The First Affiliated Hospital of Guangxi Medical University; 🇨🇳 Nanning, Guangxi, China